Reductive Adjuvant Nanosystem for Alleviated Atopic Dermatitis Syndromes
ACS Nano · 2025
DOI: 10.1021/acsnano.4c08767 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, 2025. Verfasst von Yichao Lu und 15 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, P. R. China. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Vitamin E, Nanoparticles, Adjuvants, Immunologic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Key Research and Development Program of China, National Postdoctoral Program for Innovative Talents.
Abstract (Originalsprache)
Atopic dermatitis (AD) is a recurrent and chronic inflammatory skin condition characterized by a high lifetime prevalence and significant impairment of patients' quality of life, primarily due to intense itching and discomfort. However, current pharmacological interventions provide only moderate efficacy and are frequently accompanied by adverse side effects. The immune-pathogenesis of AD involves dysregulation of the Th2 immune response and exacerbation of inflammation related to excessive reactive oxygen species (ROS). Therefore, to address these issues, in this study, we targeted the upstream pathogenesis by designing a pro-Th1 adjuvant nanoemulsion loaded with poly(I:C) and encapsulated with the ROS-scavenger vitamin E, termed PV-NE. PV-NE effectively rebalanced the Th1/Th2 immune response and reduced ROS levels both in vivo and ex vivo, leading to the restoration of immune balance in AD-affected skin and alleviation of symptoms such as lichenification and erythematous patches. In conclusion, our development of the reductive adjuvant nanosystem PV-NE demonstrates its biocompatibility and efficacy in combating AD progression without the use of immunosuppressant glucocorticoids. This has the potential to significantly impact the design and enhancement of pharmacotherapy in future clinical research aimed at curing AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, P. R. China.
- Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China.
- Zhejiang Provincial Clinical Research Center for Head & Neck Cancer, Hangzhou 310014, China.
- Zhejiang Key Laboratory of Precision Medicine Research on Head & Neck Cancer, Hangzhou 310014, China.
- Zhejiang-California International NanoSystems Institute, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, P. R. China.
- Jinhua Institute of Zhejiang University, 498 Yiwu Street, Jinhua, Zhejiang 321299, P. R. China.
ORCID-Profile: Jian You
Förderung
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases
- National Key Research and Development Program of China
- National Postdoctoral Program for Innovative Talents
- National Natural Science Foundation of China
- Basic Public Welfare Research Program of Zhejiang Province
Zitieren
APA
Lu, Y., Shan, X., Huang, J., Zhou, H., Zhu, Y., Wang, S., Luo, Z., Liu, X., Guo, X., Shi, Y., Hu, Y., Liu, H., Zhang, J., Huang, P., Luo, L., & You, J. (2025). Reductive Adjuvant Nanosystem for Alleviated Atopic Dermatitis Syndromes. ACS Nano. https://doi.org/10.1021/acsnano.4c08767
Vancouver
Lu Y, Shan X, Huang J, Zhou H, Zhu Y, Wang S, et al. Reductive Adjuvant Nanosystem for Alleviated Atopic Dermatitis Syndromes. ACS Nano. 2025. doi:10.1021/acsnano.4c08767
BibTeX
@article{Lu2025,
author = {Lu, Yichao and Shan, Xinyu and Huang, Jiaxin and Zhou, Huanli and Zhu, Ying and Wang, Sijie and Luo, Zhenyu and Liu, Xu and Guo, Xuemeng and Shi, Yingying and Hu, Yilong and Liu, Huihui and Zhang, Junlei and Huang, Ping and Luo, Lihua and You, Jian},
title = {Reductive Adjuvant Nanosystem for Alleviated Atopic Dermatitis Syndromes},
journal = {ACS Nano},
year = {2025},
doi = {10.1021/acsnano.4c08767}
}
EUVIMED